1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 09:45 ET (13:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.